Break from the Herd: Analytically Optimizing Study Site Selection
This article will describe my experiences in creating robust strategies for optimizing site selection and offer a few recommendations.
I have run across study teams that select and reuse underperforming study sites in clinical trials. I have also encountered many study sites that have selected studies that do not enroll. This article will describe my experiences in creating robust strategies for optimizing site selection and offer a few recommendations.
Break from the Herd: Target Less Crowded Study Sites
Study teams tend to base their study site selection criteria on experience and relationships with research investigators. Moreover, study teams select sites in areas with high patient population concentrations. While this method can be effective by theory, it has backfired in many cases because study teams oftentimes select research institutions that experience ‘Study Crowding Rates’. In other words, too many competing studies in the area, and number of studies compared to the amount of research staff.
Study teams should break from the herd by selecting study sites that can access untapped patient populations and are not running many trials. While some of the physicians may not be as experienced, study teams can mitigate quality risk by setting up fully electronic clinical trial capabilities, and conducting analytical monitoring.
Analyze the Data
Big data solutions now enable us to aggregate clinical trial data, as demonstrated in Figure 1.
Figure 1: Actively Recruiting Alzheimer’s Clinical Trials
Figure 1 illustrates aggregated data for all actively recruiting Alzheimer’s clinical trials in the US. There are 38 Alzheimer’s clinical trials in New York City. Due to study crowding in the NYC region, we looked at sites in the Toms River and New Jersey areas, where there are less clinical trials, and we found several research centers with solid capabilities and sufficient research experience.
Simulate Your Data
We executed advanced analytical algorithms to evaluate enrollment potential for each of the selected study sites, and we discovered that a study site in Toms River exhibited the highest enrollment potential compared to other sites in New Jersey (this algorithm was over 70% accurate in predicting enrollment in an immunology trial).
Estimates suggest that it
Always Consider the Patient
It is estimated that almost 30% of patients drop out of a clinical trial
References:
[1]
[2] Source: Seeking Predictable Subject Characteristics That Influence Clinical Trial Discontinuation. Jai Shankar K.B. Yadlapalliand Irwin G. Martin. Drug Information Journal, May 2012; vol.46:pp.313-319,first published on April 9, 2012
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Operational Strategies That Strengthened the NIMBLE Trial Design
September 16th 2025
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025